Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
J Am Podiatr Med Assoc ; 97(3): 195-202, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17507527

RESUMO

BACKGROUND: An open-label, noncomparative study was conducted to assess the safety and efficacy of ciclopirox 8% nail lacquer topical solution in patients with type 2 diabetes mellitus. METHODS: Forty-nine diabetic patients with distal subungual onychomycosis were treated once daily for 48 weeks with ciclopirox 8% nail lacquer, a topical nail solution approved for the treatment of patients with mild-to-moderate onychomycosis. RESULTS: Treatment resulted in clinical improvement in 63.4% of patients. Most patients (85.7%) had a mycologic outcome of improvement or cure, with 54.3% attaining mycologic cure. Consideration of mycologic and clinical outcomes generated a treatment outcome of improvement, success, or cure in 84.4% of patients. Moreover, patients experienced improvement in the diseased area of the nail (63.4%), nail surface (56.1%), nail color (48.8%), and nail thickness (65.9%). Ciclopirox 8% nail lacquer was safe, with treatment-related adverse events limited to infection in one patient, which resolved in 15 days; the patient completed the study. No treatment-related serious adverse events were observed. CONCLUSION: Ciclopirox 8% nail lacquer is a safe and effective treatment for distal subungual onychomycosis in patients with type 2 diabetes mellitus receiving insulin or oral hypoglycemic therapy.


Assuntos
Diabetes Mellitus Tipo 2/complicações , Dermatoses do Pé/tratamento farmacológico , Onicomicose/tratamento farmacológico , Piridonas/uso terapêutico , Administração Cutânea , Adulto , Idoso , Idoso de 80 Anos ou mais , Antifúngicos/administração & dosagem , Antifúngicos/uso terapêutico , Ciclopirox , Feminino , Dermatoses do Pé/complicações , Humanos , Laca , Masculino , Pessoa de Meia-Idade , Onicomicose/complicações , Piridonas/administração & dosagem , Resultado do Tratamento
2.
Cutis ; 72(2): 111-5, 2003 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12953933

RESUMO

Cutaneous larva migrans (CLM) is the most common tropically acquired dermatosis. It is caused by hookworm larvae, which are in the feces of infected dogs and cats. The condition occurs mainly in the Caribbean and New World, and anyone walking barefoot or sitting on a contaminated beach is at risk. Ancylostoma braziliense and Ancylostoma caninum are the most common hookworms responsible for CLM. The lesions, called creeping eruptions, are characteristically erythematous, raised and vesicular, linear or serpentine, and intensely pruritic. The conditions respond to oral and/or topical application of thiabendazole. Humans become an accidental dead-end host because the traveling parasite perishes, and its cutaneous manifestations usually resolve uneventfully within months.


Assuntos
Larva Migrans/diagnóstico , Animais , Gatos , Cães , Humanos , Larva Migrans/complicações , Larva Migrans/tratamento farmacológico , Larva Migrans/etiologia , Viagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA